Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | CDK1 | P06493 | 8/20 | 0.43 |
| ▸ | KDR | P35968 | 8/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2111997 | 0.92 | RAB9A (0.45) | RAB9ACDK1KDRCCNA2CDK2 | |
| SCHEMBL2114724 | 0.91 | RAB9A (0.44) | RAB9ACDK1KDRCCNA2CDK2 | |
| SCHEMBL2113390 | 0.88 | NPC1 (0.52) | RAB9ACDK1KDRCDK2KCNH2 | |
| SCHEMBL2117618 | 0.86 | L3MBTL1 (0.50) | RAB9ACDK1KDRNPC1JAK2 | |
| SCHEMBL2114995 | 0.85 | AURKA (0.49) | RAB9ACDK1CCNA2CDK2CDK5 | |
| SCHEMBL5524909 | 0.83 | RAB9A (0.43) | RAB9ACDK1KDRCCNA2CDK2 | |
| SCHEMBL2115678 | 0.83 | NPC1 (0.46) | RAB9AKDRNPC1MAPT | |
| SCHEMBL2114090 | 0.83 | RAB9A (0.44) | RAB9ANPC1 | |
| SCHEMBL2117157 | 0.81 | NPC1 (0.50) | RAB9ACDK1KDRCDK2KCNH2 | |
| SCHEMBL2115272 | 0.81 | TNK2 (0.42) | CDK1KDRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158641-B2 | 2-anilino-4-aminoalkyleneaminopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | RAB9A 2884/4885CDK1 173/4885KDR 2773/4885 |
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | RAB9A 2884/4885CDK1 173/4885KDR 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.